The Federal Trade Commission suspended its challenge of Amgen’s (AMGN) $27.8B acquisition of Horizon Therapeutics (HZNP), giving the agency time to weigh a settlement that would allow the deal to close with conditions, The Wall Street Journal’s Dave Michaels reports. The FTC said in a court filing late Friday that it would pause a challenge it filed in its internal court that alleged the deal violates antitrust law. The pause, effective until Sept. 18, allows the FTC’s three commissioners to decide whether the agency should settle the case, the author adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HZNP:
- Amgen-Horizon Deal: FTC Pauses Proceedings to Block Acquisition
- Paulson buys Madrigal, exits Bally’s in Q2
- Soros boosts stake in Amazon, exits position in First Horizon
- Viridian Therapeutics price target lowered to $39 from $46 at Wells Fargo
- Horizon Therapeutics reports Q2 EPS $1.20, consensus $1.11
